LIFERIVER(SH:688317)2024-04-28 07:46Financial Performance - The company's operating revenue for Q1 2024 was ¥51,227,345.41, representing a decrease of 39.27% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥26,906,914.34, an increase of 346.47% year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,817,257.34, up 267.98% from the previous year[5]. - The basic earnings per share (EPS) was ¥0.14, reflecting a significant increase of 366.67%[5]. - Total revenue for Q1 2024 was CNY 51,227,345.41, a decrease of 39.2% compared to CNY 84,348,212.48 in Q1 2023[17]. - Net profit for Q1 2024 reached CNY 26,906,914.34, compared to CNY 6,026,571.66 in Q1 2023, representing a significant increase[18]. - Total comprehensive income for Q1 2024 reached ¥21,748,318.98, compared to ¥3,658,041.80 in Q1 2023, indicating significant growth[19]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.14, up from ¥0.03 in Q1 2023, reflecting improved profitability[19]. Research and Development - The company invested ¥12,145,804.86 in R&D, which accounted for 23.71% of its operating revenue, an increase of 6.51 percentage points[6]. - Research and development expenses for Q1 2024 were CNY 12,145,804.86, down from CNY 14,504,728.20 in Q1 2023, indicating a focus on cost management[17]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥16,281,139.42, with no applicable year-over-year comparison[5]. - Cash inflows from operating activities totaled ¥102,610,733.69 in Q1 2024, down from ¥121,883,701.38 in Q1 2023, showing a decrease of approximately 15.8%[20]. - Cash outflows from operating activities decreased to ¥86,329,594.27 in Q1 2024 from ¥293,765,724.11 in Q1 2023, a reduction of about 70.7%[21]. - Net cash flow from operating activities improved to ¥16,281,139.42 in Q1 2024, compared to a negative cash flow of ¥171,882,022.73 in Q1 2023[21]. - Cash and cash equivalents at the end of Q1 2024 were ¥2,760,515,051.97, down from ¥2,923,264,994.00 at the end of Q1 2023[22]. - Cash outflow from investing activities was ¥13,076,887.54 in Q1 2024, compared to ¥42,194,813.73 in Q1 2023, indicating a decrease of approximately 69.0%[21]. - Net cash flow from investing activities was negative at -¥13,028,214.97 in Q1 2024, an improvement from -¥42,034,813.73 in Q1 2023[21]. - Cash outflow from financing activities was ¥13,443,528.37 in Q1 2024, with no corresponding figure reported for Q1 2023[21]. - The impact of exchange rate changes on cash and cash equivalents was positive at ¥1,210,497.80 in Q1 2024, contrasting with a negative impact of -¥10,541,921.43 in Q1 2023[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,044,480,941.55, a decrease of 0.73% from the end of the previous year[6]. - Total assets as of Q1 2024 amounted to CNY 4,044,480,941.55, slightly down from CNY 4,074,191,055.05 in the previous quarter[15]. - Total liabilities for Q1 2024 were CNY 205,656,899.68, a decrease from CNY 249,253,939.59 in the previous quarter[15]. - Total current assets as of March 31, 2024, were approximately ¥3.15 billion, down from ¥3.17 billion at the end of 2023, a decrease of about 0.3%[13]. Shareholder Information - The company reported a total of 3,308,708 shares held in the repurchase account, representing 1.70% of total shares[11]. - The top shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 64,969,560 shares, accounting for 64.96% of total shares[11]. - The second-largest shareholder, Ningbo Kangfeideng Investment Management Partnership, holds 6,002,000 shares, representing 3.08%[11]. - There are no known related party transactions among the top shareholders, except for the actual controllers of the largest shareholders[11]. Operational Insights - The decline in operating revenue was primarily due to a normalization of the main business and a decrease in sales of antigen and equipment products compared to the previous year[7]. - The company has not reported any significant changes in operational conditions during the reporting period[12].